SCHEMBL738136

SCHEMBL738136

Fc1ccc(C#C[Au])cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ESR1 P03372 2/20 0.36
ESR2 Q92731 2/20 0.36
APP P05067 1/20 0.34
FFAR1 O14842 1/20 0.34
NFE2L2 Q16236 1/20 0.32
MAPT P10636 1/20 0.32
MMP2 P08253 1/20 0.32
MMP9 P14780 1/20 0.32
MMP12 P39900 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
HSD17B2 P37059 1/20 0.32
GRM5 P41594 3/20 0.31
CYP1A1 P04798 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP1B1 Q16678 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL738589 0.86 CYP3A4 (0.55) CYP3A4TDP1ESR1ESR2APP
SCHEMBL736672 0.83 CYP1A2 (0.48) CYP3A4TDP1ESR1ESR2APP
SCHEMBL737970 0.78 GRM5 (0.39) CYP3A4TDP1ESR1ESR2FFAR1
SCHEMBL736790 0.77 APP (0.44) CYP3A4TDP1APPMMP2MMP9
SCHEMBL18702923 0.77 CYP3A4 (0.67) CYP3A4TDP1ESR1ESR2NFE2L2
SCHEMBL10874458 0.77 CYP3A4 (0.67) CYP3A4TDP1ESR1ESR2NFE2L2
SCHEMBL2543676 0.77 CYP3A4 (0.67) CYP3A4TDP1ESR1ESR2NFE2L2
SCHEMBL738372 0.76 ALDH1A1 (0.45) CYP3A4TDP1ESR1ESR2MAPT
SCHEMBL739038 0.76 CASP3 (0.49) CYP3A4TDP1MAPTCA12CA2
SCHEMBL738401 0.76 CYP3A4 (0.39) CYP3A4TDP1ESR1ESR2FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1847545-B1 SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME UBE INDUSTRIES (JP) 2013-03-06 EP disclosed
US-8137821-B2 Substituted ethynyl gold-nitrogen containing heterocyclic carbene complex and organic electroluminescent device using the same UBE INDUSTRIES, LTD. (JP) 2012-03-20 US disclosed
US-20090091243-A1 Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same UBE INDUSTRIES, LTD. (JP) 2009-04-09 US disclosed
EP-1847545-A1 SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME Ube Industries, Ltd. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090091243-A1 Substituted Ethynyl Gold-Nitrogen Containing Heterocyclic Carbene Complex and Organic Electroluminescent Device Using the Same ACSL3, ATXN2L, ACSL1 CYP3A4 1880/4885TDP1 4435/4885ESR1 1263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.